BioSpace News Archive

argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for VYVGART® (efgartigimod alfa injection), a first-in-class neonatal Fc receptor (FcRn) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

BioNTX and grant partners Dallas College and the DFW Hospital Council Foundation collaborated with Swiss American CDMO to launch the Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT).

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.

Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World Congress on Gastrointestinal Cancer (ESMO GI).

Bristol-based deep tech ecosystem, Science Creates, has launched an engineering biology accelerator programme to support life science start-ups and innovators in developing ground-breaking advancements in healthcare, the environment, and quality of life.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), is pleased to announce the results of its 2023 annual meeting of shareholders

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announces that certain of its 27,461,157 common share purchase warrants

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that on May 31, 2023,

Dr. Brian Cornblatt, the Chief Medical Officer of BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE:8MV) (“BioHarvest” or “the company”), delivered a keynote address on the “HealthConf” stage at the Collision conference in Toronto on Thursday.